
Zynerba Pharmaceuticals ZYNE
Quartalsbericht 2023-Q2
hinzugefügt 14.08.2023
Land |
|
IPO-Jahr |
2015 |
Branche |
Arzneimittelhersteller |
Börse |
NASDAQ GLOBALSPB |
Anteile |
42.7 M |
Marktkapitalisierung |
$ 55.5 M |
EBITDA (LTM) |
$ -36.6 M |
P/E (LTM) |
- |
P/S (LTM) |
162.2 |
EPS (LTM) |
-0.86 |
Andere Aktien der Branche "Arzneimittelhersteller"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | ||
|
Aurora Cannabis
ACB
|
$ 3.31 | - | $ 86.3 M | NYSE | ||
|
China Pharma Holdings
CPHI
|
$ 0.63 | - | $ 11 M | NYSE American | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | ||
|
Avadel Pharmaceuticals plc
AVDL
|
- | - | $ 2.06 B | Nasdaq Global Select Market | ||
|
Cronos Group
CRON
|
$ 2.53 | 0.4 % | $ 1.31 B | Nasdaq Global Market | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | ||
|
Emergent BioSolutions
EBS
|
$ 8.02 | -0.37 % | $ 411 M | NYSE,SPB | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 3.19 | 4.59 % | $ 44.9 M | Nasdaq Global Select Market | ||
|
Bausch Health Companies
BHC
|
$ 5.0 | -2.15 % | $ 1.82 B | NYSE | ||
|
Harrow Health
HROW
|
$ 35.17 | 3.43 % | $ 1.29 B | Nasdaq Global Market | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | ||
|
Pacira BioSciences
PCRX
|
$ 22.82 | 0.75 % | $ 1.06 B | Nasdaq Global Select Market,SPB | ||
|
Evolus
EOLS
|
$ 4.61 | -1.5 % | $ 297 M | Nasdaq Global Market | ||
|
Rockwell Medical
RMTI
|
$ 1.05 | 2.45 % | $ 24.5 M | Nasdaq Global Market | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | ||
|
Relmada Therapeutics
RLMD
|
$ 6.07 | 3.58 % | $ 240 M | Nasdaq Global Select Market,SPB | ||
|
Solid Biosciences
SLDB
|
$ 6.9 | -3.43 % | $ 604 M | Nasdaq Global Select Market,SPB | ||
|
Sundial Growers
SNDL
|
$ 1.36 | - | $ 3.37 M | Nasdaq Global Select Market | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 2.32 | -9.02 % | $ 2.88 M | Nasdaq Capital Market | ||
|
OrganiGram Holdings
OGI
|
$ 1.37 | 0.37 % | $ 402 M | Nasdaq Global Select Market | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | ||
|
Tilray
TLRY
|
$ 6.41 | -0.62 % | $ 3.96 B | Nasdaq Global Select Market | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | ||
|
Veru
VERU
|
$ 2.33 | 1.3 % | $ 314 M | Nasdaq Capital Market | ||
|
Viatris
VTRS
|
$ 13.45 | 1.17 % | $ 16.1 B | Nasdaq Global Select Market,SPB | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | ||
|
SCYNEXIS
SCYX
|
$ 0.88 | 0.25 % | $ 43.9 M | Nasdaq Global Select Market | ||
|
cbdMD
YCBD
|
$ 0.78 | 2.52 % | $ 3.36 M | NYSE American | ||
|
TherapeuticsMD
TXMD
|
$ 2.35 | 1.73 % | $ 24.5 M | Nasdaq Global Select Market | ||
|
Organogenesis Holdings
ORGO
|
$ 2.41 | -2.43 % | $ 317 M | Nasdaq Capital Market | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | ||
|
Perrigo Company plc
PRGO
|
$ 9.6 | 0.31 % | $ 1.33 B | NYSE | ||
|
Canopy Growth Corporation
CGC
|
$ 0.95 | -1.52 % | $ 102 M | Nasdaq Global Select Market | ||
|
Assertio Holdings
ASRT
|
$ 15.92 | 13.68 % | $ 102 M | Nasdaq Capital Market | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB |